Fibrodysplasia ossificans progressiva (FOP), also known as myositis ossificans progressive, is a rare inherited connective tissue disorder characterized by abnormal bone development in ligaments, tendons, and skeletal muscles. Precisely, FOP causes the body's skeletal muscles and soft connective tissues to undergo a metamorphosis, transforming into bone, gradually locking joints and making movement difficult. FOP is inherited as an autosomal dominant trait with complete penetrance. Standard therapies available for FOP are; corticosteroids and non-steroidal anti-inflammatory medication for pain and swelling associated with FOP; occupational therapy; and genetic counselling. Regeneron Pharmaceuticals Inc. is in the process of developing REGN2477 as an activin A antibody which act as an activin modulator for the treatment of FOP. Some of the companies in FOP pipeline are Clementia Pharmaceuticals Inc. and Regeneron Pharmaceuticals Inc. among others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.